Home › Steatotic Liver Disease › Texas
Steatotic Liver Disease clinical trials in Texas
20 studies for Steatotic Liver Disease are looking for participants at sites in Texas.
Cities in Texas
- San Antonio17 studies
- Houston13 studies
- Austin13 studies
- Dallas9 studies
- Brownsville7 studies
- Round Rock7 studies
- Fort Worth6 studies
- Sugar Land6 studies
- Arlington6 studies
- Waco6 studies
- Grand Prairie5 studies
- Carrollton4 studies
- Pasadena4 studies
- Edinburg4 studies
- The Woodlands4 studies
- Lewisville3 studies
- League City3 studies
- Corpus Christi3 studies
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- and 5 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Bellaire
- and 4 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07701993A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
- American Research Corporation, Austin
- Advanced Medical Trials, Georgetown
- American Research Corporation at The Texas Liver Institute, San Antonio
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07527910A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- American Research Corporation, Austin
- Pinnacle Clinical Research - Austin, Austin
- Methodist Dallas Medical Center, Dallas
- and 5 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- IMA Clinical Research Austin, Austin
- American Research Corporation, Austin
- Pinnacle Clinical Research, Austin
- and 26 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Arlington
- Akero Clinical Study Site, Austin
- Akero Clinical Study Site, Austin
- and 28 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Brownsville
- and 12 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Pinnacle Clinical Research, Austin
- Bellaire Clinical Research, Bellaire
- South Texas Research Institute (STRI) - Brownsville, Brownsville
- and 14 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- and 30 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Amarillo
- 89bio Clinical Study Site, Austin
- 89bio Clinical Study Site, Austin
- and 21 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374Quantifying Hepatic Mitochondrial Fluxes in Humans
- Texas Diabetes Institute - University Health System, San Antonio
- University of Texas Health Science Center at San Antonio, San Antonio
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT05305287A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Dallas
- and 4 more
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Arlington
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- and 16 more
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- GSK Investigational Site, Austin
- and 10 more
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
- GSK Investigational Site, San Antonio
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Jun 9, 2026 · NCT07358546Evaluating the Pharmacokinetics and Safety of Miricorilant
- Site# 433, San Antonio
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated May 26, 2026 · NCT07553663Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population
- Methodist Dallas Medical Center, Dallas
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 13, 2026 · NCT06225193A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Pioneer Research Solutions, Houston
RecruitingPhase 1/2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Apr 16, 2026 · NCT05648214NAFLD Clinical Care Pathway
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 14, 2025 · NCT06671886Evaluation of Non-Invasive Tests for Metabolic Liver Disease
- First Surgical Hospital, Bellaire
- Endeavor Clinical Trials, San Antonio
RecruitingObservational study
Ages 18 to 75 · All sexes · Updated Aug 14, 2025 · NCT07122700From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.